Bristol-Myers wraps up Amylin acquisition
Bristol-Myers Squibb Co. has completed its acquisition of Amylin Pharmaceuticals Inc. Under the deal announced early last month, Bristol-Myers agreed to buy Amylin for $31 per share in cash, pursuant to a cash tender offer and second-step merger, for an aggregate purchase price of about $5.